Function-first ligandomics for ocular vascular research and drug target discovery

Xin Rong, Hong Tian, Liu Yang, Wei Li

Research output: Contribution to journalShort survey

Abstract

Human eyes may develop different vascular diseases with neovascularization and/or leakage, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), retinopathy of prematurity, corneal neovascularization and intraocular tumors. A breakthrough in therapy is the advent and approval of vascular endothelial growth factor (VEGF) inhibitors. However, anti-VEGF drugs not only have limited efficacy to treat AMD, DME and PDR but also are not approved for other ocular indications. The key to addressing these unmet clinical needs is to develop novel therapies against VEGF-independent angiogenic factors or signaling pathways for alternative or combination therapy. We recently developed the first paradigm of ligandomics for global mapping of cell-wide ligands as well as disease-selective ligands. Therapies targeting disease-selective angiogenic or vascular leakage factors likely have high efficacy, minimal side effects, wide therapeutic windows and relatively low drug attrition rates. A critical challenge is how to distinguish between genuine drug targets and spurious hits identified by high-throughput ligandomics. Here we exploited the unique advantages of the eye and extracellular ligands by combining ligandomics with “function-first” and/or “therapy-first” analyses to efficiently characterize functional activity, disease selectivity, pathogenic role and therapeutic potential of identified ligands. The innovative function- or therapy-first ligandomics will systematically and reliably delineate disease-selective angiogenic or vascular leakage factors and markedly facilitate ocular vascular research and ligand-guided targeted anti-angiogenic therapy.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalExperimental Eye Research
Volume182
DOIs
StatePublished - May 1 2019

Fingerprint

Drug Discovery
Blood Vessels
Research
Ligands
Vascular Endothelial Growth Factor A
Macular Edema
Macular Degeneration
Diabetic Retinopathy
Therapeutics
Pharmaceutical Preparations
Corneal Neovascularization
Retinopathy of Prematurity
Angiogenesis Inducing Agents
Therapeutic Uses
Vascular Diseases

Keywords

  • Angiogenic factor
  • Comparative ligandomics
  • Drug target discovery
  • Ligandomics
  • Retina
  • Target validation
  • Vascular disease
  • Vascular leakage factor

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Function-first ligandomics for ocular vascular research and drug target discovery. / Rong, Xin; Tian, Hong; Yang, Liu; Li, Wei.

In: Experimental Eye Research, Vol. 182, 01.05.2019, p. 57-64.

Research output: Contribution to journalShort survey

@article{5d78d91df09c4ae095a0cbffe52a9467,
title = "Function-first ligandomics for ocular vascular research and drug target discovery",
abstract = "Human eyes may develop different vascular diseases with neovascularization and/or leakage, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), retinopathy of prematurity, corneal neovascularization and intraocular tumors. A breakthrough in therapy is the advent and approval of vascular endothelial growth factor (VEGF) inhibitors. However, anti-VEGF drugs not only have limited efficacy to treat AMD, DME and PDR but also are not approved for other ocular indications. The key to addressing these unmet clinical needs is to develop novel therapies against VEGF-independent angiogenic factors or signaling pathways for alternative or combination therapy. We recently developed the first paradigm of ligandomics for global mapping of cell-wide ligands as well as disease-selective ligands. Therapies targeting disease-selective angiogenic or vascular leakage factors likely have high efficacy, minimal side effects, wide therapeutic windows and relatively low drug attrition rates. A critical challenge is how to distinguish between genuine drug targets and spurious hits identified by high-throughput ligandomics. Here we exploited the unique advantages of the eye and extracellular ligands by combining ligandomics with “function-first” and/or “therapy-first” analyses to efficiently characterize functional activity, disease selectivity, pathogenic role and therapeutic potential of identified ligands. The innovative function- or therapy-first ligandomics will systematically and reliably delineate disease-selective angiogenic or vascular leakage factors and markedly facilitate ocular vascular research and ligand-guided targeted anti-angiogenic therapy.",
keywords = "Angiogenic factor, Comparative ligandomics, Drug target discovery, Ligandomics, Retina, Target validation, Vascular disease, Vascular leakage factor",
author = "Xin Rong and Hong Tian and Liu Yang and Wei Li",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.exer.2019.03.009",
language = "English (US)",
volume = "182",
pages = "57--64",
journal = "Experimental Eye Research",
issn = "0014-4835",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Function-first ligandomics for ocular vascular research and drug target discovery

AU - Rong, Xin

AU - Tian, Hong

AU - Yang, Liu

AU - Li, Wei

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Human eyes may develop different vascular diseases with neovascularization and/or leakage, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), retinopathy of prematurity, corneal neovascularization and intraocular tumors. A breakthrough in therapy is the advent and approval of vascular endothelial growth factor (VEGF) inhibitors. However, anti-VEGF drugs not only have limited efficacy to treat AMD, DME and PDR but also are not approved for other ocular indications. The key to addressing these unmet clinical needs is to develop novel therapies against VEGF-independent angiogenic factors or signaling pathways for alternative or combination therapy. We recently developed the first paradigm of ligandomics for global mapping of cell-wide ligands as well as disease-selective ligands. Therapies targeting disease-selective angiogenic or vascular leakage factors likely have high efficacy, minimal side effects, wide therapeutic windows and relatively low drug attrition rates. A critical challenge is how to distinguish between genuine drug targets and spurious hits identified by high-throughput ligandomics. Here we exploited the unique advantages of the eye and extracellular ligands by combining ligandomics with “function-first” and/or “therapy-first” analyses to efficiently characterize functional activity, disease selectivity, pathogenic role and therapeutic potential of identified ligands. The innovative function- or therapy-first ligandomics will systematically and reliably delineate disease-selective angiogenic or vascular leakage factors and markedly facilitate ocular vascular research and ligand-guided targeted anti-angiogenic therapy.

AB - Human eyes may develop different vascular diseases with neovascularization and/or leakage, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), retinopathy of prematurity, corneal neovascularization and intraocular tumors. A breakthrough in therapy is the advent and approval of vascular endothelial growth factor (VEGF) inhibitors. However, anti-VEGF drugs not only have limited efficacy to treat AMD, DME and PDR but also are not approved for other ocular indications. The key to addressing these unmet clinical needs is to develop novel therapies against VEGF-independent angiogenic factors or signaling pathways for alternative or combination therapy. We recently developed the first paradigm of ligandomics for global mapping of cell-wide ligands as well as disease-selective ligands. Therapies targeting disease-selective angiogenic or vascular leakage factors likely have high efficacy, minimal side effects, wide therapeutic windows and relatively low drug attrition rates. A critical challenge is how to distinguish between genuine drug targets and spurious hits identified by high-throughput ligandomics. Here we exploited the unique advantages of the eye and extracellular ligands by combining ligandomics with “function-first” and/or “therapy-first” analyses to efficiently characterize functional activity, disease selectivity, pathogenic role and therapeutic potential of identified ligands. The innovative function- or therapy-first ligandomics will systematically and reliably delineate disease-selective angiogenic or vascular leakage factors and markedly facilitate ocular vascular research and ligand-guided targeted anti-angiogenic therapy.

KW - Angiogenic factor

KW - Comparative ligandomics

KW - Drug target discovery

KW - Ligandomics

KW - Retina

KW - Target validation

KW - Vascular disease

KW - Vascular leakage factor

UR - http://www.scopus.com/inward/record.url?scp=85063193403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063193403&partnerID=8YFLogxK

U2 - 10.1016/j.exer.2019.03.009

DO - 10.1016/j.exer.2019.03.009

M3 - Short survey

VL - 182

SP - 57

EP - 64

JO - Experimental Eye Research

JF - Experimental Eye Research

SN - 0014-4835

ER -